Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

被引：0
|
作者：
Stopeck, Alison T. [1 ]
Unger, Joseph M. [2 ]
Rimsza, Lisa M. [3 ]
Farnsworth, Brent [3 ]
LeBlanc, Michael [2 ]
Iannone, Maria [1 ]
Fisher, Richard I. [4 ]
Miller, Thomas P. [1 ]
机构：
[1] Arizona Canc Ctr, Tucson, AZ USA
[2] SW Oncol Grp, Seattle, WA USA
[3] Univ Arizona, Tucson, AZ USA
[4] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：260 / 261
页数：2
相关论文
共 50 条
  • [41] A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) us subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
    Younes, Anas
    Zinzani, Pier Luigi
    Sehn, Laurie Helen
    Johnson, Peter W. M.
    Gascoyne, Randy D.
    Ahmedi, Tahamtan
    Bellew, Kevin M.
    Verrneulen, Jessica
    Zhuang, Sen Hong
    Sun, Stevan
    Staudt, Louis M.
    Wilson, Wyndham Hopkins
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [42] Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-cell non-Hodgkin's lymphoma (B-NHL).
    Tobinai, K
    Watanabe, T
    Ogura, M
    Morishima, Y
    Itoh, K
    Igarashi, T
    Hotta, T
    Kinoshita, T
    Mori, S
    Ohashi, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [43] Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL).
    Habermann, TM
    Weller, EA
    Morrison, VA
    Cassileth, PA
    Cohn, JB
    Dakhil, SR
    Gascoyne, RD
    Woda, B
    Fisher, RI
    Peterson, BA
    Horning, SJ
    BLOOD, 2003, 102 (11) : 6A - 6A
  • [44] Rituximab plus reduced-dose cyclophosphamide, doxorubicin, vincristine and prednisone (RD R-CHOP) chemotherapy is feasible for very elderly patients (≥80 years) with B-cell lymphoma: analysis of treatment outcome
    Shi, Zhan
    Tang, Xi
    Wang, Jingwen
    Shen, Qianwen
    Chen, Xi
    Chen, Jiayan
    Zhuang, Jie
    JOURNAL OF CHEMOTHERAPY, 2016, 28 (06) : 487 - 493
  • [45] Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lLymphoma (DLBCL) overcomes Bcl2-associated chemotherapy resistance.
    Mounier, N
    Briere, J
    Gisselbrecht, C
    Gaulard, P
    Lederlin, P
    Sebban, C
    Bosly, A
    Morel, P
    Tilly, H
    Bouabdallah, R
    Reyes, F
    Coiffier, B
    BLOOD, 2002, 100 (11) : 161A - 161A
  • [46] ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).
    Sehn, Laurie Helen
    Kahl, Brad S.
    Matasar, Matthew J.
    Lenz, Georg
    Izutsu, Koji
    Zhao, Weili
    Tao, Lin
    Calvo, Roser
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study
    Morschhauser, Franck
    Feugier, Pierre
    Flinn, Ian W.
    Gasiorowski, Robin E.
    Greil, Richard
    Illes, Arpad
    Johnson, Nathalie A.
    Larouche, Jean-Francois
    Lugtenburg, Pieternella J.
    Patti, Caterina
    Salles, Gilles
    Trneny, Marek
    de Vos, Sven
    Mir, Farheen
    Kornacker, Martin
    Punnoose, Elizabeth A.
    Samineni, Divya
    Szafer-Glusman, Edith
    Petrich, Adam
    Sinha, Arijit
    Mobasher, Mehrdad
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [48] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
    Hainsworth, J. D.
    Arrowsmith, E. R.
    Mccleod, M.
    Fayad, L. E.
    Hamid, O.
    Davis, L.
    Lin, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
  • [49] Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Patti, Caterina
    Belada, David
    Samoilova, Olga
    Suh, Cheolwon
    Leppae, Sirpa
    Rai, Shinya
    Turgut, Mehmet
    Jurczak, Wojciech
    Cheung, Matthew C.
    Gurion, Ronit
    Yeh, Su-Peng
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Chiattone, Carlos Sergio
    Balasubramanian, Sriram
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Zhuang, Sen Hong
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham
    Fisher, Richard I.
    Engert, Andreas
    Stadtmauer, Edward A.
    Wei, Lee-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1285 - +
  • [50] R-CHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0433
    Friedberg, Jonathan W.
    Unger, Joseph M.
    Burack, W. Richard
    Gopal, Ajay K.
    Raju, Robert N.
    Nademanee, Auayporn P.
    Kaminski, Mark S.
    Li, Hongli
    Press, Oliver W.
    Miller, Thomas P.
    Fisher, Richard I.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (03) : 382 - 389
12345